At the recent meeting of the American Society of Clinical Oncology (ASCO), Dr. John Leonard, the director of the Weill Cornell Lymphoma Program, presented the results of the CALGB 50401 trial. The trial compared lenalidomide plus rituximab versus lenalidomide alone in 94 patients with previously treated follicular lymphoma.
Although significant side effects were similar in both treatment arms, the patients treated with the lenalidomide plus rituximab were more likely to respond to treatment (75% vs. 49%) and remain on treatment compared to lenalidomide alone. Based on these results, the investigators concluded that the lenalidomide-rituximab regimen should be considered as a platform for addition of new drugs in future studies.
Click here to read the published abstract.